Abstract
BACKGROUND AND PURPOSE: To test the design and feasibility of a very large randomised controlled trial assessing the efficacy and safety of antithrombotic therapy started within 48 hours of symptom onset in patients with suspected acute ischaemic stroke. DESIGN: Randomised controlled multicentre open study, with a 3 x 2 factorial design, allocating patients to: medium dose subcutaneous heparin (12,500 units twice per day), versus low dose subcutaneous heparin (5000 units twice per day) versus no heparin; and aspirin (300 mg daily) versus no aspirin. Treatment was given for two weeks or until discharge from hospital if sooner. RESULTS: 984 patients were randomised. CT was performed in 924 (94%) (before randomisation in 622/984 (63%). Within 14 days: 97 patients had died (10%), 30 (3.0%) had a fatal or non-fatal recurrent ischaemic stroke, nine (0.9%) had fatal or non-fatal recurrent stroke due to intracranial haemorrhage, and eight (0.8%) had a fatal or non-fatal pulmonary embolus. At six months, vital status was known for 975 patients (99%), of whom 210 (22%) were dead, 373 (38%) were alive but dependent, and 225 (23%) were independent but not fully recovered. CONCLUSIONS: The trial procedures proved practicable and a wide variety of patients were recruited. Sample size calculation based on the event rates confirmed that reliable evidence on the balance of risk and benefit of early antithrombotic therapy might require a study with more than 20,000 patients. Recruitment rates in the pilot study indicated that if about 200 hospitals participated, recruitment could be completed by 1997.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bamford J. Clinical examination in diagnosis and subclassification of stroke. Lancet. 1992 Feb 15;339(8790):400–402. doi: 10.1016/0140-6736(92)90085-h. [DOI] [PubMed] [Google Scholar]
- Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990 Jan;53(1):16–22. doi: 10.1136/jnnp.53.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991 Jun 22;337(8756):1521–1526. doi: 10.1016/0140-6736(91)93206-o. [DOI] [PubMed] [Google Scholar]
- Sandercock P. A., van den Belt A. G., Lindley R. I., Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):17–25. doi: 10.1136/jnnp.56.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sandercock P., Willems H. Medical treatment of acute ischaemic stroke. Lancet. 1992 Feb 29;339(8792):537–539. doi: 10.1016/0140-6736(92)90348-7. [DOI] [PubMed] [Google Scholar]
- White S. J., Freedman L. S. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer. 1978 May;37(5):849–857. doi: 10.1038/bjc.1978.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yusuf S., Collins R., Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984 Oct-Dec;3(4):409–422. doi: 10.1002/sim.4780030421. [DOI] [PubMed] [Google Scholar]